You are here: Industry Insights > NMBA

News List

Macleods Pharmaceuticals issues recall due to NMBA impurities europeanpharmaceuticalreview
July 05, 2019
Macleods has issued a recall of 32 lots of drug products that contained trace amounts of NMBA impurities.
Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity drugs
May 20, 2019
Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity.
NEWS FDA finds another carcinogenic impurity in ARB blood pressure drug europeanpharmaceuticalreview
April 10, 2019
FDA is ‘deeply concerned’ about a third type of nitrosamine impurity detected in angiotensin II receptor blocker (ARB) medicines…
FDA provides Update on ARB Drug Product Investigation americanpharmaceuticalreview
March 06, 2019
The U.S. Food and Drug Administration (FDA) is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and